A case study on the effect of neutralizing antibodies to interferon beta 1b in multiple sclerosis patients followed for 3 years with monthly imaging

Clinical and Experimental Immunology

Volumn 150, Issue 1, 2007, Pages 61-67

  Chiu, A W ^a   Ehrmantraut, M ^a   Richert, N D ^a   Ikonomidou, V N ^a   Pellegrini, S ^a   McFarland, H F ^a   Frank, J A ^a   Bagnato, F ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

IFN ; Magnetic resonance imaging; Multiple sclerosis; Neutralizing antibodies

Indexed keywords

INTERFERON BETA SERINE; METHYLPREDNISOLONE; NEUTRALIZING ANTIBODY; PREDNISONE;

ADULT; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL;

ADULT; ANTIBODIES; BRAIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; TREATMENT OUTCOME;

EID: 34548538497     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2007.03467.x     Document Type: Article

References (22)

1. IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology 1996 47:889 94.
2. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983 33:1444 52.
3. Bagnato F, Pozzilli C. Pharmacological methods to overcome IFN-beta antibody formation in the treatment of multiple sclerosis. Expert Opin Invest Drugs 2003 7:1153 63.
4. Sorensen PS, Deisenhammer F, Duda P et al. Guidelines on use of anti-IFN-β antibodies in multiple sclerosis: a report of an EFNS Task Force on IFN-β in multiple sclerosis. Eur J Neurol 2005 12:817 27.
5. Namaka M, Pollitt-Smith M, Gupta A et al. The clinical importance of neutralizing antibodies in relapsing-remitting multiple sclerosis. Curr Med Res Opin 2006 22:223 39.
6. Goodin DS, Frohman EM, Hurwitz B et al. Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report. Neurology 2007 68:977 84.
7. Petkau J, White RA, Ebers GC et al. Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis. Mult Scler 2004 10:126 38.
8. Barbero P, Bergui M, Versino E et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis (INCOMIN Trial) II: analysis of MRI responses to treatment and correlation with Nab. Mult Scler 2006 12:72 6.
9. Panitch H, Miller A, Paty D, Weinshenker B for the North American Study Group on Interferon beta-1b in Secondary Progressive MS. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology 2004 63:1788 95.
10. Polman C, Kappos L, White R et al. Neutralizing antibodies during treatment of secondary progressive MS with interferon β-1b. Neurology 2003 60:37 43.
11. McFarland HF, Frank JA, Albert PS et al. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol 1992 32:758 66.
12. Poser CM, Paty DW, Scheinberg L et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983 13:227 31.
13. Files JG, Gray JL, Do LT et al. A novel sensitive and selective bioassay for human type I interferons. J Interferon Cytokine Res 1998 18:1019 24.
14. Pungor E Jr., Files JG, Gabe JD et al. A novel bioassay for the determination of neutralizing antibodies to IFN-β1b. J Interferon Cytokine Res 1998 18:1025 30.
15. Stone LA, Frank JA, Albert PS et al. The effect of interferon-beta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis. Ann Neurol 1995 37:611 9.
16. Rice GP, Paszner B, Oger J et al. The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon beta-1b. Neurology 1999 52:1277 9.
17. Bellomi F, Scagnolari C, Tomassini V et al. Fate of neutralizing and binding antibodies to IFN beta in MS patients treated with IFN beta for 6 years. J Neurol Sci 2003 215:3 8.
18. Gilli F, Hoffmann F, Sala F et al. Qualitative and quantitative analysis of antibody response against IFNb in patients with multiple sclerosis. Mult Scler 2006 12:738 46.
19. Pachner AR, Narayan K, Pak E. Multiplex analysis of expression of three IFN beta-induced genes in antibody-positive MS patients. Neurology 2006 66:444 6.
20. Herndon RM, Rudick RA, Munschauer FE III. et al. Eight-year immunogenicity and safety of interferon beta-1a-Avonex® treatment in patients with multiple sclerosis. Mult Scler 2003 11:409 19.
21. Reske D, Walser A, Haupt WF, Petereit HF. Long-term persisting interferon beta-1b neutralizing antibodies after discontinuation of treatment. Acta Neurol Scand 2004 109:66 70.
22. Pozzilli C, Antonini G, Bagnato F et al. Monthly corticosteroids decrease neutralizing antibodies to IFNβ 1b: a randomized trial in multiple sclerosis. J Neurol 2002 249:50 60.